Duodenocutaneous fistula in rats as a model for "wound healing-therapy" in ulcer healing: the effect of pentadecapeptide BPC 157, L-nitro-arginine methyl ester and L-arginine.

Skorjanec S, Kokot A, Drmic D, Radic B, Sever M, Klicek R, Kolenc D, Zenko A, Lovric Bencic M, Belosic Halle Z, Situm A, Zivanovic Posilovic G and 5 more

Show all authors

Masnec S, Suran J, Aralica G, Seiwerth S, Sikiric P

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society1 Aug 2015Cited by 23 (Europe PMC)

PMID26348082PepBankPUB-26348082

Publisher pageAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with duodenocutaneous fistula, BPC‑157 fully counteracted persistent defects.
In plain wordsIn rats with a duodenum-skin fistula, BPC‑157 fully counteracted the persistent defects seen in controls.
Peptide
BPC-157
Outcome
DecreasePersistent fistula defects
Study
ratn: not reported in source
Comparator
Control duodenocutaneous fistula rats
Outcome group
Wound healing · Gastrointestinal
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal or peroral in drinking water · 21 daysAs given in this study (rat).
Source sentences
Summary
Duodenocutaneous fistula-rats maintained persistent defects, continuous fistula leakage, sphincter failure, mortality rate at 40% until the 4(th) day, all fully counteracted in all BPC 157-rats.
1 context sentence(design, population, supporting numbers)
Summary · context
Duodenocutaneous fistula-rats received BPC 157 (10 μg/kg or 10 ng/kg, intraperitoneally or perorally (in drinking water)), L-NAME (5 mg/kg intraperitoneally), L-arginine (100 mg/kg intraperitoneally) alone and/or together, throughout 21 days.
Report a problemFND-2634808201
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with duodenocutaneous fistula, BPC‑157 fully counteracted continuous fistula leakage.
In plain wordsIn rats with a duodenum-skin fistula, BPC‑157 fully stopped the continuous leakage seen in controls.
Peptide
BPC-157
Outcome
DecreaseContinuous fistula leakage
Study
ratn: not reported in source
Comparator
Control duodenocutaneous fistula rats
Outcome group
Wound healing · Gastrointestinal
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal or peroral in drinking water · 21 daysAs given in this study (rat).
Source sentences
Summary
Duodenocutaneous fistula-rats maintained persistent defects, continuous fistula leakage, sphincter failure, mortality rate at 40% until the 4(th) day, all fully counteracted in all BPC 157-rats.
1 context sentence(design, population, supporting numbers)
Summary · context
Duodenocutaneous fistula-rats received BPC 157 (10 μg/kg or 10 ng/kg, intraperitoneally or perorally (in drinking water)), L-NAME (5 mg/kg intraperitoneally), L-arginine (100 mg/kg intraperitoneally) alone and/or together, throughout 21 days.
Report a problemFND-2634808202
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with duodenocutaneous fistula, BPC‑157 fully counteracted sphincter failure.
In plain wordsIn rats with a duodenum-skin fistula, BPC‑157 fully counteracted the sphincter failure seen in controls.
Peptide
BPC-157
Outcome
DecreaseSphincter failure
Study
ratn: not reported in source
Comparator
Control duodenocutaneous fistula rats
Outcome group
Wound healing · Gastrointestinal
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal or peroral in drinking water · 21 daysAs given in this study (rat).
Source sentences
Summary
Duodenocutaneous fistula-rats maintained persistent defects, continuous fistula leakage, sphincter failure, mortality rate at 40% until the 4(th) day, all fully counteracted in all BPC 157-rats.
1 context sentence(design, population, supporting numbers)
Summary · context
Duodenocutaneous fistula-rats received BPC 157 (10 μg/kg or 10 ng/kg, intraperitoneally or perorally (in drinking water)), L-NAME (5 mg/kg intraperitoneally), L-arginine (100 mg/kg intraperitoneally) alone and/or together, throughout 21 days.
Report a problemFND-2634808203
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with duodenocutaneous fistula, BPC‑157 fully counteracted the mortality of 40% until the 4th day seen in controls.
In plain wordsIn rats with a duodenum-skin fistula, BPC‑157 fully counteracted the deaths seen in controls.
Peptide
BPC-157
Outcome
DecreaseMortality until day 4
Study
ratn: not reported in source
Comparator
Control duodenocutaneous fistula rats
Outcome group
Mortality · Gastrointestinal
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal or peroral in drinking water · 21 daysAs given in this study (rat).
Source sentences
Summary
Duodenocutaneous fistula-rats maintained persistent defects, continuous fistula leakage, sphincter failure, mortality rate at 40% until the 4(th) day, all fully counteracted in all BPC 157-rats.
1 context sentence(design, population, supporting numbers)
Summary · context
Duodenocutaneous fistula-rats received BPC 157 (10 μg/kg or 10 ng/kg, intraperitoneally or perorally (in drinking water)), L-NAME (5 mg/kg intraperitoneally), L-arginine (100 mg/kg intraperitoneally) alone and/or together, throughout 21 days.
Report a problemFND-2634808204
05AnimalAnimal study (in vivo)Efficacy outcome
In rats with duodenocutaneous fistula, BPC‑157 rapidly improved the complete presentation, with the maximal volume instilled already at the 7th day.
In plain wordsIn rats with a duodenum-skin fistula, BPC‑157 quickly improved the whole condition, with full volume reached by day 7.
Peptide
BPC-157
Outcome
IncreaseMaximal volume instilled
Study
ratn: not reported in source
Comparator
Control duodenocutaneous fistula rats
Outcome group
Wound healing · Gastrointestinal
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal or peroral in drinking water · 21 daysAs given in this study (rat).
Measurements
Time to maximal instilled volume
7 day
BPC 157 rats
Source sentences
Summary
The BPC 157-rats experienced rapidly improved complete presentation (maximal volume instilled already at 7(th) day).
1 context sentence(design, population, supporting numbers)
Summary · context
Duodenocutaneous fistula-rats received BPC 157 (10 μg/kg or 10 ng/kg, intraperitoneally or perorally (in drinking water)), L-NAME (5 mg/kg intraperitoneally), L-arginine (100 mg/kg intraperitoneally) alone and/or together, throughout 21 days.
Report a problemFND-2634808205
06AnimalAnimal study (in vivo)Efficacy outcome
In rats with duodenocutaneous fistula, BPC‑157 annulled the aggravating effects of L-NAME.
In plain wordsIn rats with a duodenum-skin fistula, BPC‑157 cancelled the worsening effect of L-NAME.
Peptide
BPC-157
Outcome
DecreaseL-NAME-induced aggravation of fistula course
Study
ratn: not reported in source
Comparator
L-NAME alone
Outcome group
Wound healing · Gastrointestinal
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal or peroral in drinking water · 21 daysAs given in this study (rat).
Source sentences
Summary
while BPC 157 annulled the L-NAME effects (L-NAME + L-arginine; L-NAME + BPC 157; L-NAME + L-arginine + BPC 157 brought below the level of the control).
1 context sentence(design, population, supporting numbers)
Summary · context
Duodenocutaneous fistula-rats received BPC 157 (10 μg/kg or 10 ng/kg, intraperitoneally or perorally (in drinking water)), L-NAME (5 mg/kg intraperitoneally), L-arginine (100 mg/kg intraperitoneally) alone and/or together, throughout 21 days.
Report a problemFND-2634808206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:56 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.